Compare Crispr Therapeutics AG (CRSP) vs Carvana Co (CVNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Carvana Co — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Carvana Co trades at $63.73 (market cap $69.55B). The key difference: Carvana Co is far larger — about 14.3× Crispr Therapeutics AG's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, Carvana Co nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Carvana Co for 28 Days on average.
| CRSP | CVNA | |
|---|---|---|
Market Cap | $4.88B | $69.55B |
Volume | 2,861,747 | 7,671,750 |
Sector | Health | Consumer Cyclical |
52-Week High | $74.92 | $95.69 |
52-Week Low | $44.34 | $56.27 |
Typical Hold Time | 77 Days | 28 Days |
Enterprise Value | $3.30B | $72.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
Carvana (CVNA) trades at $63.21, up 0.72% with strong fundamental momentum including 10 consecutive quarters of record profitability. Revenue surged 52% in Q2 FY26 to $20.32B annually, while net income reached $1.41B with a 6.26% margin. Technical indicators show bearish momentum with key support at $61-62, though RSI levels remain neutral. The company continues expanding capacity to meet robust demand, with same-day delivery recently launched in Minneapolis.
CVNA presents growth potential with analyst consensus target of $84.07 (33% upside), but faces risks from high debt levels ($5.26B long-term) and volatile cash flow patterns. The stock's elevated P/E of 33.44 and EV/EBITDA of 507.31 suggest premium valuation, requiring sustained execution to justify. Competitive pressures in online auto retail and interest rate sensitivity remain key watchpoints for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Carvana Co
Carvana Co is an e-commerce platform for buying and selling used cars. The company derives revenue from used vehicle sales, wholesale vehicle sales and other sales and revenues. The other sales and revenues include sales of loans originated and sold in securitization transactions or to financing partners, commissions received on VSCs and sales of GAP waiver coverage.
Read more on CVNA →
